Screener
Nuvectis Pharma, Inc. NVCT Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Nuvectis Pharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 9:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-055318
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| TOTAL LIABILITIES | 11,178 | 13,296 |
| COMMITMENTS AND CONTINGENCIES, see Note 3 | ||
| SHAREHOLDERS’ EQUITY, see Note 4 | ||
| Common Shares, $0.00001 par value – 60,000,000 shares authorized as of March 31, 2026, and December 31, 2025, 26,525,533, and 25,676,798 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | * | * |
| Additional paid in capital | 119,957 | 118,100 |
| Accumulated deficit | (105,737) | (99,687) |
| TOTAL SHAREHOLDERS’ EQUITY | 14,220 | 18,413 |
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $25,398 | $31,709 |
Item 1. Financial Statements
FAQ
- What is Nuvectis Pharma, Inc.'s total equity?
- Nuvectis Pharma, Inc. (NVCT) reported total equity of $14.22M in Q1 2026.
- How has Nuvectis Pharma, Inc.'s total equity changed year-over-year?
- Nuvectis Pharma, Inc.'s total equity decreased by 32.1% year-over-year, from $20.95M to $14.22M.
- What is the long-term trend for Nuvectis Pharma, Inc.'s total equity?
- Over 5 years (2020 to 2025), Nuvectis Pharma, Inc.'s total equity has grown at a 349.8% compound annual growth rate (CAGR), from -$10K to $18.41M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Nuvectis Pharma, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude